Ipamorelin

What it is

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a selective growth hormone secretagogue, binding the ghrelin receptor (GHS-R1a) on pituitary somatotrophs to stimulate GH release. It belongs to the GHRP (growth hormone-releasing peptide) class along with GHRP-2, GHRP-6, and hexarelin, but its defining feature is selectivity — it produces clean GH release with minimal effects on cortisol, prolactin, ACTH, or appetite.

Ipamorelin was developed by Helsinn Therapeutics in the late 1990s with the explicit goal of capturing the GH-releasing activity of earlier GHRPs while eliminating their off-target effects. Early-phase clinical trials confirmed this selectivity profile. Helsinn pursued ipamorelin for postoperative ileus (a different indication based on GHRPs’ effects on GI motility), but the development program was discontinued in 2011 after a Phase III trial failed to meet its primary endpoint.

Ipamorelin is not FDA-approved for any indication. It is available through licensed compounding pharmacies and has become the standard GHRP component in modern clinical GH-axis protocols, having largely replaced GHRP-2, GHRP-6, and hexarelin in this role.

Mechanism of action

Ipamorelin binds the ghrelin receptor (GHS-R1a), which is the same receptor activated by endogenous ghrelin. Activation triggers GH release from pituitary somatotrophs through pathways that complement GHRH signaling:

• Direct GH release: activates intracellular signaling that triggers GH secretion independent of GHRH input
• Synergy with GHRH: simultaneous activation of GHRH receptors and GHS-R1a produces GH release that is substantially greater than either pathway alone — the basis for combining ipamorelin with GHRH analogs
• Somatostatin antagonism: suppresses somatostatin tone, which is the primary inhibitor of GH release. This “releases the brake” on GH secretion.
• Selective activation: at clinical doses, ipamorelin activates GH release pathways without producing significant ACTH/cortisol elevation, prolactin elevation, or appetite stimulation that characterize earlier GHRPs

The half-life is approximately 2 hours — long enough to produce a sustained GH release response, short enough to preserve overall pulsatile patterns when dosed once daily.

Research findings

Ipamorelin has more clinical trial data than most compounded peptides we prescribe, owing to the formal pharmaceutical development program:

Pharmacokinetic and pharmacodynamic studies: Phase I trials in healthy volunteers demonstrated dose-dependent GH release with peak effects within 30–60 minutes of administration. Ipamorelin produced GH release equivalent to GHRP-6 at similar doses but without the cortisol, prolactin, or appetite effects of GHRP-6.

Postoperative ileus (failed Phase III): ipamorelin was studied for resolution of postoperative ileus based on GHRPs’ effects on GI motility (independent of GH effects). The Phase III trial in 2011 did not show benefit in this indication, and the development program was discontinued. This is unrelated to its GH-releasing activity.

Combined GHRH + ipamorelin studies: multiple smaller studies have documented the synergistic GH release achievable with combined administration, supporting the clinical practice of combining these peptides.

How we use it at The Tide

We almost exclusively prescribe ipamorelin in combination with a GHRH analog — typically CJC-1295 (no DAC), or alternatively sermorelin. Standalone ipamorelin produces GH release but the synergistic effect with GHRH analogs is meaningfully larger.

Standard protocol:

• Ipamorelin 200 mcg + CJC-1295 (no DAC) 100 mcg, combined in a single subcutaneous injection
• Administered 5 nights per week at bedtime
• 12-week cycles with 4–6 week breaks between cycles
• Baseline and 90-day IGF-1 monitoring; standard metabolic panel cadence

Indications: adults with documented age-related GH axis decline (low-normal or below-range IGF-1 for age) and clinical concerns related to body composition, sleep quality, training recovery, or general vitality.

Why we use ipamorelin rather than other GHRPs:

• vs. GHRP-2: equivalent GH release without significant cortisol or prolactin elevation
• vs. GHRP-6: equivalent GH release without significant appetite stimulation (which can be problematic in metabolic patients)
• vs. hexarelin: better long-term safety profile (hexarelin produces tachyphylaxis and cortisol elevation that limit chronic use)

Side effects and contraindications

Ipamorelin has an excellent tolerability profile:

• Rare flushing, mild head fullness shortly after injection
• Injection site reactions
• Vivid dreams when first starting
• Joint discomfort or water retention only at excessive doses (unusual at standard dosing)

The selective receptor profile means cortisol and prolactin levels remain stable, appetite is not significantly affected, and the broader endocrine and metabolic disruptions sometimes seen with older GHRPs do not occur at clinical doses.

Contraindicated in: active malignancy, pregnancy and breastfeeding, pituitary disease, severe obesity, active diabetic retinopathy.

What we don’t yet know

Although ipamorelin has more formal clinical research than many compounded peptides, its long-term use in adult GH-axis support has not been formally studied in large trials. Most clinical evidence supporting current usage patterns comes from practitioner experience extending the Phase I/II pharmacology research. Optimal dose, optimal cycle length, and optimal frequency of use over multi-year time horizons are not formally established. The role of ipamorelin (alone or combined) in patients with normal age-adjusted IGF-1 who simply want “optimization” is debatable and outside our clinical practice — we prescribe based on documented physiological need, not aspirational use. Ipamorelin represents a peptide with strong mechanistic basis and clean pharmacology, used appropriately as part of GH-axis support protocols in patients who meet appropriate criteria.